Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) dropped 3.2% on Friday . The company traded as low as $5.75 and last traded at $5.76, with a volume of 715,003 shares traded. The stock had previously closed at $5.95.

ZIOP has been the topic of a number of research analyst reports. Wells Fargo & Co. restated a “sell” rating on shares of Ziopharm Oncology in a research note on Thursday, May 19th. Zacks Investment Research upgraded shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research note on Tuesday, August 16th. Griffin Securities restated a “buy” rating and issued a $21.00 target price on shares of Ziopharm Oncology in a research note on Monday, August 15th. Finally, Mizuho upped their target price on shares of Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 11th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $9.75.

The stock’s 50-day moving average price is $5.30 and its 200-day moving average price is $6.75. The firm’s market cap is $759.49 million.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.52 million. The company’s revenue was up 525.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.11) EPS. Analysts predict that Ziopharm Oncology Inc. will post ($1.34) EPS for the current year.

A number of institutional investors have recently modified their holdings of ZIOP. Swiss National Bank increased its position in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the period. Morgan Stanley increased its position in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.